

Washington State Pharmacy and Therapeutics Committee
Drug Utilization Review Board
Date: August 18, 2021
Time: 9 a.m. to 4 p.m.
Teams Meeting

9 a.m.	Welcome & Introductions Drug Utilization Review (DUR) Board Convenes (Reviews drug classes for the Apple Health PDL)	Ginni Buccola, Committee Chair
9:05 a.m.	Antipsychotics / Antimanic Agents: <ul style="list-style-type: none"> • Antipsychotics 2nd Generation • Antipsychotics Combinations <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 2nd Generation and Combinations ○ Motion Parkinson’s Psychotic Disorder 	Umang Patel, Magellan
9:35 a.m.	Cytokine and CAM Antagonists <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
10:50 a.m.	Break	All
11 a.m.	Movement Disorder Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
11:15 a.m.	Ophthalmic Agents: <ul style="list-style-type: none"> • Glaucoma Agents • Immunomodulators <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Umang Patel, Magellan
11:40 a.m.	Respiratory Agents: Pulmonary Fibrosing Agents <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
12 p.m.	Lunch	All
12:30 p.m.	Smoking Deterrents: Misc – Other <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Umang Patel, Magellan
12:45 p.m.	Oncology Agents- Oral: <ul style="list-style-type: none"> • Androgen Biosynthesis Inhibitors • Antiandrogens • Antineoplastics - Misc Combinations • Hedgehog Pathway Inhibitors • Multikinase Inhibitors 	Umang Patel, Magellan

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> • Tyrosine Kinase Inhibitors • Braf Kinase Inhibitors • Cyclin Dependent Kinases (CDK) Inhibitors • FGFR Kinase Inhibitors • MEK Inhibitors • MTOR Kinase Inhibitors • Poly (ADP-Ribose) Polymerase (PARP) Inhibitors • Retinoids • Topoisomerase Inhibitors • Tropomyosin Receptor Kinase Inhibitors <ul style="list-style-type: none"> ○ Stakeholder input* ○ Motion 	Magellan
2:35 p.m.	Break	All
2:45 p.m.	Apple Health Policy: 27.17.00- GLP1 Agonists <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Marissa Tabile, HCA
3:05 p.m.	Apple Health Policy: 58.12.00- Antidepressants: Serotonin Modulators <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
3:25 p.m.	Apple Health Policy: 61.40.00.AA- Armodafinil/Modafinil <ul style="list-style-type: none"> • Stakeholder input* • Motion 	Ryan Taketomo, HCA
4 p.m.	Drug Utilization Review Board Adjourns	Ginni Buccola, Committee Chair

For all Apple Health (Medicaid) questions, please email AppleHealthPharmacyPolicy@hca.wa.gov.

** Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.